Search
for
Sort by
Research 121–150 of 1000+
- A Case of Steatocystoma Multiplex in a Psoriatic Patient during Treatment with Anti-IL-12/23
- P19-041-23 The Association Between Sugar-Sweetened Beverages (SSBs) and Hair Loss in Young Women
- Integrative Nutritional Mechanisms of Keyora Lycopene 23 in 1 Man's Multi-Vitamin in Erectile Dysfunction, Male Infertility, Prostatic Disorders, and Metabolic Dysregulation
- Integrative Nutritional Mechanisms of Keyora Lycopene 23 in 1 Man's Multi-Vitamin in Erectile Dysfunction, Male Infertility, Prostatic Disorders, and Metabolic Dysregulation
- P22-023-23 Pilot Study Protocol on Application of Non-Invasive Vitamin D Hair Test and Screening E-Tool for Indigenous Populations in the Great Northern Plains
- Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment
- Case 2-2022: An Adolescent Male in Cardiac Arrest 3 Days After Liver Transplantation for End-Stage Liver Disease
- Pediatric androgenetic alopecia: a retrospective review of clinical characteristics, hormonal assays and metabolic syndrome risk factors in 23 patients
- Delayed Diagnosis of Congenital Adrenal Hyperplasia Due to 3β-Hydroxysteroid Dehydrogenase Type 2 Deficiency
- Type 2 Cytokine–Dependent Skin Barrier Regulation in Personalized 2-Dimensional and 3-Dimensional Skin Models of Atopic Dermatitis: A Pilot Study
- Peer Review #3 of "Computational drug repositioning based on side-effects mined from social media (v0.2)"
- Retrospective Review of Folliculitis Decalvans in 23 Patients with Course and Treatment Analysis of Long-standing Cases
- Refractory folliculitis decalvans treated with adalimumab: A case series of 23 patients
- 42175 PASI improvement in the first 12 weeks from the Phase 3 VOYAGE 1, VOYAGE 2, ORION and ECLIPSE guselkumab clinical trials
- Application of 2-Chloro-7-Nitrobenzo-2-Oxa-1, 3-Diazol (NBDCL) for Spectrophotometric Determination of Finasteride in Pharmaceutical Formulation
- Clinical, morphological and immunohistochemical characterization of cutaneous lymphocytosis in 23 cats
- Electronic States of Epigallocatechin-3-Gallate in Water and in 1,2-dipalmitoyl-sn-glycero-3-phospho-(1′-rac-glycerol) (Sodium Salt) Liposomes
- Dependence of anxiolytic effects of the dipeptide TSPO ligand GD-23 on neurosteroid biosynthesis
- A case of Acne Vulgaris in 23 years old female patient
- A Systematic Review of Antiaging Effects of 23 Traditional Chinese Medicines
- Immunofluorescence Tomography: High-resolution 3-D reconstruction by serial-sectioning of methacrylate embedded tissues and alignment of 2-D immunofluorescence images
- Reviewer #1 (Public Review): CaBP1 and 2 enable sustained CaV1.3 calcium currents and synaptic transmission in inner hair cells
- The synthesis of (−)-4-methyl-8-chloro-trans-1,2,3,4,4a,5,6,10b-octahydrobenzo-[f]-quinolin-3-one-[3-14C] (LY300502-14C]) via a circuitous route
- Tuning Scaffold Properties of New 1,4-Substituted Pyrrolo[3,2-c]quinoline Derivatives Endowed with Anticancer Potential, New Biological and In Silico Insights
- Polikistik Over Sendromlu Adölesanlarda Serum Ürokortin 2, Ürokortin 3 ve Antimüllerian Hormon Düzeyleri
- Peer Review Report For: Pattern changes of cutaneous dermatoses among Iraqi women preceding and during the COVID-19 pandemic [version 3; peer review: 2 approved]
- Pharmacokinetic parameters and mechanisms of inhibition of rat type 1 and 2 steroid 5α-reductases: determinants for different in vivo activities of GI198745 and finasteride in the rat 3 3Abbreviations: r5AR1, rat 5α-reductase 1; r5AR2, rat 5α-reductase 2; and DHT, dihydrotestosterone.
- Synthesis, Anticancer and Molecular Docking Studies of 2-(4-chlorophenyl)-5-aryl-1,3,4-Oxadiazole Analogues
- CLINICAL NUTRITION PROGRAM IMPROVES POST CONCUSSION SYMPTOMS IN 23 YEAR OLD FEMALE
- 26143 Time to scalp hair, eyebrow, and eyelash improvement in patients with alopecia areata treated with baricitinib in the phase 2 portion of the phase 2/3 BRAVE-AA1 study